Skip Navigation LinksHome > September 1999 - Volume 18 - Issue 9 > Safety and immunogenicity of heptavalent pneumococcal CRM197...
Pediatric Infectious Disease Journal:
Original Studies

Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers

SHINEFIELD, HENRY R. MD; BLACK, STEVEN MD; RAY, PAULA MPH; CHANG, IH PHD; LEWIS, NED MPH; FIREMAN, BRUCE MA; HACKELL, JILL MD; PARADISO, PETER R. PHD; SIBER, GEORGE MD; KOHBERGER, ROBERT PHD; MADORE, DACE V. PHD; MALINOWSKI, FRANK J. MD*; KIMURA, ALAN MD, PHD†; LE, CHINH MD; LANDAW, IRENE MD; AGUILAR, JANET MD; HANSEN, JOHN BA

Collapse Box

Abstract

Objectives. The objectives of this study were (1) to determine the safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate (PNCRM7) vaccine in infants and (2) to determine the effect of concurrent hepatitis B immunization during the primary series and the effect of concurrent diphtheria and tetanus toxoid and acellular pertussis [DTaP (ACEL-IMUNE)] and conjugate CRM197 Haemophilus influenzae type b [HbOC (HibTITER) immunization at time of the booster dose on the safety and immunogenicity of PNCRM7 and these other concurrently administered vaccines.

Methods. This was a randomized double-blinded study in 302 healthy infants in the Northern California Kaiser Permanente (NCKP) Health Plan. Infants received either PNCRM7 vaccine or meningococcal group C conjugate vaccine as a control at 2, 4 and 6 months of age and a booster at 12 to 15 months of age. Study design permitted the evaluation of immunology and safety of concurrent administration of routine vaccines. Antibody titers were determined on blood samples drawn before and 1 month after the primary series and the booster dose.

Results. After the third dose of PNCRM7 geometric mean concentrations (GMCs) ranged from 1.01 for serotype 9V to 3.72 μg/ml for serotype 14. More than 90% of all subjects had a post-third dose titer of ≥0.15 μg/ml for all serotypes, and the percentage of infants with a post-third dose titer of ≥1.0 μg/ml ranged from 51% for type 9V to 89% for type 14. After the PNCRM7 booster dose, the GMCs of all seven serotypes increased significantly over both post-Dose 3 and pre-Dose 4 antibody levels. In the primary series there were no significant differences in GMCs of pneumococcal antibodies between the subjects given PNCRM7 alone or concurrently with hepatitis B vaccine. At the toddler dose concurrent administration of PNCRM7 and DTaP and HbOC resulted in a near conventional threshold for statistical significance of a post-Dose 4 GMC for serotype 23F [alone 6.75 μg/ml vs. concurrent 4.11 μg/ml (P = 0.057)] as well as significantly lower antibody GMCs for H. influenzæ polyribosylribitol phosphate, diphtheria toxoid, pertussis toxin and filamentous hemagglutinin. For all antigens there were no differences between study groups in defined antibody titers that are considered protective.

Conclusion. We conclude that PNCRM7 vaccine was safe and immunogenic. When this vaccine was administered concurrently at the booster dose with DTaP and HbOC vaccines, lower antibody titers were noted for some of the antigens when compared with the antibody response when PNCRM7 was given separately. Because the GMCs of the booster responses were all generally high and all subjects achieved similar percentages above predefined antibody titers, these differences are probably not clinically significant.

© 1999 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.